A pivotal phase 3 study to evaluate WTX101 in patients with Wilson Disease.

Trial Profile

A pivotal phase 3 study to evaluate WTX101 in patients with Wilson Disease.

Planning
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Bis-choline tetrathiomolybdate (Primary)
  • Indications Hepatolenticular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2016 According to Wilson Therapeutics media release, company is planning to initiate the study in 2017.
    • 10 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top